MA40929A - Procédé de production d'anticorps à affinité élevée - Google Patents
Procédé de production d'anticorps à affinité élevéeInfo
- Publication number
- MA40929A MA40929A MA040929A MA40929A MA40929A MA 40929 A MA40929 A MA 40929A MA 040929 A MA040929 A MA 040929A MA 40929 A MA40929 A MA 40929A MA 40929 A MA40929 A MA 40929A
- Authority
- MA
- Morocco
- Prior art keywords
- antigen
- antibodies
- cells
- production process
- lymphoid
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un procédé d'identification de cellules qui expriment des anticorps spécifiques d'antigènes avec une forte affinité de liaison pour un antigène monomère. En utilisant un tri cellulaire activé par fluorescence, les cellules exprimant des anticorps spécifiques d'antigène à haute affinité sont sélectionnées à partir d'une population de cellules immunitaires isolées d'un mammifère qui a été immunisé ou exposé à l'antigène. Les acides nucléiques codant pour les anticorps à haute affinité peuvent ensuite être clonés dans d'autres cellules lymphoïdes et non lymphoïdes où l'anticorps peut être exprimé et à partir desquelles les anticorps peuvent être sécrétés.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462079899P | 2014-11-14 | 2014-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40929A true MA40929A (fr) | 2017-09-20 |
Family
ID=54754774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040929A MA40929A (fr) | 2014-11-14 | 2015-11-13 | Procédé de production d'anticorps à affinité élevée |
Country Status (6)
Country | Link |
---|---|
US (3) | US10752698B2 (fr) |
EP (2) | EP4134378A1 (fr) |
DK (1) | DK3218396T3 (fr) |
ES (1) | ES2939555T3 (fr) |
MA (1) | MA40929A (fr) |
WO (1) | WO2016077666A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4134378A1 (fr) | 2014-11-14 | 2023-02-15 | Regeneron Pharmaceuticals, Inc. | Procédé de génération d'anticorps à haute affinité |
CN111351935A (zh) * | 2018-12-20 | 2020-06-30 | 上海恒润达生生物科技有限公司 | Bcma-car亲和力检测方法 |
CN112625128B (zh) * | 2020-08-06 | 2022-11-08 | 熙源安健医药(上海)有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
CA3197426A1 (fr) * | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Procedes d'obtention d'anticorps qui se lient a des proteines transmembranaires et cellules qui les produisent |
BR112023021256A2 (pt) | 2021-04-20 | 2023-12-12 | Regeneron Pharma | Anticorpos humanos para artemina e métodos de uso dos mesmos |
CA3226042A1 (fr) | 2021-07-05 | 2023-01-12 | Regeneron Pharmaceuticals, Inc. | Utilisation d'anticorps pour former des reponses d'anticorps a un antigene |
IL312101A (en) * | 2021-10-18 | 2024-06-01 | Adimab Llc | Anti-activin A antibodies, compositions and uses thereof |
WO2023147107A1 (fr) * | 2022-01-31 | 2023-08-03 | Byomass Inc. | Affections myéloprolifératives |
WO2024015816A1 (fr) | 2022-07-12 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050048578A1 (en) * | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
US8497138B2 (en) * | 2010-09-30 | 2013-07-30 | Genetix Limited | Method for cell selection |
RU2585153C2 (ru) * | 2010-12-02 | 2016-05-27 | Аимм Терапьютикс Б.В. | Средства и способы получения высокоаффинных антител |
GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
EP4134378A1 (fr) * | 2014-11-14 | 2023-02-15 | Regeneron Pharmaceuticals, Inc. | Procédé de génération d'anticorps à haute affinité |
-
2015
- 2015-11-13 EP EP22199396.7A patent/EP4134378A1/fr active Pending
- 2015-11-13 DK DK15802270.7T patent/DK3218396T3/da active
- 2015-11-13 EP EP15802270.7A patent/EP3218396B1/fr active Active
- 2015-11-13 US US15/526,522 patent/US10752698B2/en active Active
- 2015-11-13 MA MA040929A patent/MA40929A/fr unknown
- 2015-11-13 ES ES15802270T patent/ES2939555T3/es active Active
- 2015-11-13 WO PCT/US2015/060523 patent/WO2016077666A1/fr active Application Filing
-
2020
- 2020-08-07 US US16/987,639 patent/US11808766B2/en active Active
-
2023
- 2023-10-02 US US18/375,755 patent/US20240036043A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3218396A1 (fr) | 2017-09-20 |
US10752698B2 (en) | 2020-08-25 |
US20240036043A1 (en) | 2024-02-01 |
EP3218396B1 (fr) | 2022-12-28 |
WO2016077666A1 (fr) | 2016-05-19 |
DK3218396T3 (da) | 2023-03-06 |
US20170327593A1 (en) | 2017-11-16 |
EP4134378A1 (fr) | 2023-02-15 |
US20200369783A1 (en) | 2020-11-26 |
US11808766B2 (en) | 2023-11-07 |
ES2939555T3 (es) | 2023-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40929A (fr) | Procédé de production d'anticorps à affinité élevée | |
EP4303229A3 (fr) | Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe | |
GT201700162A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
PH12017501114A1 (en) | Anti-c5 antibodies and methods of use | |
MA42542B1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
MA41287A (fr) | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement | |
SA518391704B1 (ar) | C5 أجسام مضادة لـ وطرق لاستخدامها | |
MX2023001360A (es) | Anticuerpos anti-c5 y metodos de uso. | |
CU20190087A7 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
EA033433B1 (ru) | Антитела к tau и их применение | |
AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
MX2018013520A (es) | Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control. | |
MA43794B1 (fr) | Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie | |
AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
CU20180129A7 (es) | Anticuerpos anti-basigin humanizados | |
EA202091569A1 (ru) | Моноклональные антитела и способы их применения | |
MX353464B (es) | Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles. | |
PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
EP4300101A3 (fr) | Peptides antigéniques et leurs utilisations pour diagnostiquer et traiter l'autisme | |
MX2017005644A (es) | Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas. | |
EA202193234A1 (ru) | Сортировка с контрселекцией с применением пептидов со сходными последовательностями | |
WO2017176950A3 (fr) | Vaccin contre le ver du cœur, procédés et utilisations associés | |
UA124330C2 (uk) | Спосіб кількісного визначення антирабічного антигену in vitro в інактивованих антирабічних вакцинах | |
BR112016017597A2 (pt) | Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo |